What is your second line therapy for patients with EGPA with mainly pulmonary and sinonasal features who did not respond to mepolizumab 300 mg/month and still require high doses of steroid?   


Answer from: at Academic Institution
Comments
at University of California (San Francisco) School of Medicine
Pembrolizumab (Keytruda) is a checkpoint inhibitor...
at Massachusetts General Hospital
Yes, thank you for catching that mistake. I had me...
Sign in or Register to read more

Answer from: at Community Practice